Our Director Downstream Manufacturing, Serge M. Stamm, set out, in collaboration with scientists of XL-protein, (PhD) Michaela Gebauer, to develop a clonal and high-yield mammalian cell line for the manufacturing of a hyperactive human DNase I with extended plasma half-life. The results of this research have now been published in the 15th Anniversary edition of Pharmaceutics with the Special Issue “Improvement of Drug Bioavailability”. Find out how, in order to expand the therapeutic utility of human DNase I, a variant of the enzyme was developed that has both a prolonged systemic half-life and a higher catalytic activity compared to Dornase alfa, the recombinant form of DNase I approved for inhaled therapy of cystic fibrosis. The research is part of Rentschler Biopharma’s collaboration with XL-protein GmbH to manufacture a long-acting, hyperactive recombinant human deoxyribonuclease I (DNase I). Combining XL-protein’s proprietary PASylation® technology and Rentschler Biopharma’s expertise in bioprocess development, a process was developed with high yield for this modified DNase I which exhibits both strongly increased activity and an extended pharmacokinetic profile. For more insights, please visit our website: https://lnkd.in/e4YiFmiH #RentschlerBiopharma #CDMO
Congratulations Serge!
Expert in mammalian process and cell line development. University lecturer.
1mocongratulations, Serge M. Stamm, I remember discussing with you about this topic at your internal meeting a while ago and being quite intrigued! great to see this has come to full fruition!